Curemark Adds Two Autism Trial Sites in California

[Guest guest]

Curemark Adds Two Autism Trial Sites in California

RYE, N.Y., Oct. 27/PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug

research and development company focused on the treatment of neurological

diseases, announced that it has added two sites in California to its Phase III

clinical trial program for CM-AT, the company's autism treatment.

The new sites are the University of California San Francisco (UCSF) and the

Neuropsychiatric Research Center of Orange County (NRC) in Santa Ana. Curemark

opened CM-AT clinical trial enrollment at the UC MIND Institute in

Sacramento earlier this year. The company now has 15 trial sites across the

U.S. targeting to enroll a total 170 children in the study.

" We now have trial sites participating in the autism study in major centers

throughout California, " said Dr. Joan Fallon, Curemark founder and CEO. " There

has been substantial interest in the CM-AT trials and we're continuing to expand

the number of sites around the country. "

CM-AT, which has received Fast Track status from the FDA, targets enzyme

deficiencies in autistic children, resulting in an inability to digest protein.

The inability to digest protein affects the availability of amino acids, the

building blocks of chemicals essential for brain function. If approved, CM-AT

will be one of the first therapies to address the underlying physiology of

autism.

For information on enrolling in the Curemark CM-AT autism trials, log on to

www.clinicaltrials.gov and search " Curemark. "

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of

neurological and other diseases, especially those with dysautonomic components,

by addressing certain key gastrointestinal/pancreatic secretory deficiencies.

The company's initial products are based upon breakthrough observations by its

founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children

with autism and ADHD.